{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:17:23Z","timestamp":1789762643781,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229836"],"award-info":[{"award-number":["R01CA229836"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.slasd.2024.100201","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T08:21:13Z","timestamp":1733732473000},"page":"100201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications"],"prefix":"10.1016","volume":"30","author":[{"given":"David A.","family":"Close","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-3091","authenticated-orcid":false,"given":"Paul A.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2024.100201_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrd3144","article-title":"Anticancer Drug Development: the grand challenges","volume":"9","author":"Hait","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.slasd.2024.100201_bib0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","article-title":"High drug attrition rates\u2013where are we going wrong?","volume":"8","author":"Hutchinson","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.slasd.2024.100201_bib0003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","article-title":"Preclinical development of molecular-targeted agents for cancer","volume":"8","author":"Ocana","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.slasd.2024.100201_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2017.03.002","article-title":"The production of 3D tumor spheroids for cancer drug discovery","volume":"23","author":"Sant","year":"2017","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1089\/adt.2015.662","article-title":"Production of uniform 3D microtumors in hydrogel microwell arrays for measurement of viability, morphology, and signaling pathway activation","volume":"13","author":"Singh","year":"2015","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0006","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/1087057116650965","article-title":"Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures","volume":"21","author":"Boehnke","year":"2016","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.slasd.2024.100201_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020615","article-title":"Sarcoma spheroids and organoids-promising tools in the era of personalized medicine","volume":"19","author":"Colella","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2024.100201_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2472630317697251","article-title":"3D culture as a clinically relevant model for personalized medicine","volume":"22","author":"Fong","year":"2017","journal-title":"SLAS Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201600295","article-title":"Bringing 3D tumor models to the clinic - predictive value for personalized medicine","volume":"12","author":"Halfter","year":"2017","journal-title":"Biotechnol J"},{"issue":"9","key":"10.1016\/j.slasd.2024.100201_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183074","article-title":"Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine","volume":"12","author":"Jeppesen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.slasd.2024.100201_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-21200-8","article-title":"In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening","volume":"8","author":"Mazzocchi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2024.100201_bib0012","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","article-title":"Tumor organoids as a pre-clinical cancer model for drug discovery","volume":"24","author":"Weeber","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.slasd.2024.100201_bib0013","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jocn.2020.04.107","article-title":"Patient-derived tumor organoid predicts drugs response in glioblastoma: a step forward in personalized cancer therapy?","volume":"78","author":"Loong HH","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.slasd.2024.100201_bib0014","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier L","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2024.100201_bib0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling Development and Disease with Organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.slasd.2024.100201_bib0016","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Sandro Nuciforo","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.slasd.2024.100201_bib0017","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/modpathol.3800674","article-title":"Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma","volume":"19","author":"Chan","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.slasd.2024.100201_bib0018","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4254\/wjh.v9.i18.797","article-title":"Systemic treatment of hepatocellular carcinoma: past, present and future","volume":"9","author":"Cidon","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.slasd.2024.100201_bib0019","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5582\/ddt.2015.01047","article-title":"Systemic therapies for hepatocellular carcinoma","volume":"9","author":"Ge","year":"2015","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.slasd.2024.100201_bib0020","article-title":"Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J Carcinog"},{"key":"10.1016\/j.slasd.2024.100201_bib0021","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1078-0432.1319.11.3","article-title":"Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells","volume":"11","author":"Wong","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.slasd.2024.100201_bib0022","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: consider the population","volume":"47","author":"Mittal","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.slasd.2024.100201_bib0023","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.slasd.2024.100201_bib0024","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","article-title":"\u03b2-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis","volume":"148","author":"Monga","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.slasd.2024.100201_bib0025","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.slasd.2024.100201_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.slasd.2024.100201_bib0027","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.slasd.2024.100201_bib0028","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1158\/0008-5472.CAN-07-6469","article-title":"Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest","volume":"68","author":"Gho","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2024.100201_bib0029","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"S.H.A.R.P. Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.slasd.2024.100201_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.slasd.2024.100201_bib0031","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.32802","article-title":"TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk","volume":"78","author":"Lam YK","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.slasd.2024.100201_bib0032","doi-asserted-by":"crossref","DOI":"10.1089\/adt.2016.741","article-title":"Reconfiguring the AR-TIF2 protein-protein interaction HCS assay in prostate cancer cells and characterizing the hits from a LOPAC screen","author":"Fancher","year":"2016","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0033","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12154-015-0131-7","article-title":"Design and activity of AP endonuclease-1 inhibitors","volume":"8","author":"Feng","year":"2015","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.slasd.2024.100201_bib0034","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/adt.2013.524","article-title":"High-content pSTAT3\/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines","volume":"12","author":"Johnston","year":"2014","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1089\/adt.2015.663","article-title":"HCS campaign to identify selective inhibitors of IL-6-Induced STAT3 pathway activation in head and neck cancer cell lines","volume":"13","author":"Johnston","year":"2015","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0036","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-4939-7357-6_20","article-title":"The generation of three-dimensional head and neck cancer models for drug discovery in 384-Well Ultra-Low attachment microplates","volume":"1683","author":"Close","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.slasd.2024.100201_bib0037","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/adt.2018.896","article-title":"High content screening characterization of head and neck squamous cell carcinoma multicellular tumor spheroid cultures generated in 384-Well ultra-low attachment plates to screen for better cancer drug leads","volume":"17","author":"Kochanek","year":"2019","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/2472555219896999","article-title":"Maximizing the value of cancer drug screening in multicellular tumor spheroid cultures: a case study in five head and neck squamous cell carcinoma cell lines","volume":"25","author":"Kochanek","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100201_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/adt.2017.812","article-title":"High-content screening comparison of cancer drug accumulation and distribution in two-dimensional and three-dimensional culture models of head and neck cancer","volume":"16","author":"Shan","year":"2018","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.slasd.2021.10.008","article-title":"Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines","volume":"27","author":"David A Close","year":"2022","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100201_bib0041","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.slasd.2024.100201_bib0042","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gr.154492.113","article-title":"Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma","volume":"23","author":"Kan","year":"2013","journal-title":"Genome Res"},{"key":"10.1016\/j.slasd.2024.100201_bib0043","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.slasd.2024.100201_bib0044","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.slasd.2024.100201_bib0045","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/0008-5472.CAN-05-3077","article-title":"The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells","volume":"66","author":"Grantab","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2024.100201_bib0046","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-214","article-title":"Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib","volume":"12","author":"Grantab","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.slasd.2024.100201_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00296245","article-title":"Aspects of cytotoxic drug penetration, with particular reference to anthracyclines","volume":"19","author":"Kerr","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.slasd.2024.100201_bib0048","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.slasd.2024.100201_bib0049","first-page":"878","article-title":"Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy","volume":"8","author":"Tannock","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.slasd.2024.100201_bib0050","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.slasd.2024.100201_bib0051","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/excr.1997.3717","article-title":"Monitoring uptake of ellipticine and its fluorescence lifetime in relation to the cell cycle phase by flow cytometry","volume":"236","author":"Sailer","year":"1997","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.slasd.2024.100201_bib0052","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/adt.2010.0281","article-title":"Characterization and optimization of a novel protein-protein interaction biosensor hcs assay to identify disruptors of the interactions between p53 and hDM2","volume":"8","author":"Dudgeon","year":"2010","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0053","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/adt.2012.456","article-title":"Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic Dynein-mediated transport of glucocorticoid receptor to the nucleus","volume":"10","author":"Johnston","year":"2012","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2024.100201_bib0054","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/2472555217689884","article-title":"A novel multiparametric drug-scoring method for high-throughput screening of 3D multicellular tumor spheroids using the celigo image cytometer","volume":"22","author":"Cribbes","year":"2017","journal-title":"SLAS Discov"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:05:11Z","timestamp":1737695111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555224000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":54,"alternative-id":["S2472555224000637"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100201","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100201"}}